MX2011012199A - Derivados de benzoxazolona como inhibidores de la sintasa de aldosterona. - Google Patents
Derivados de benzoxazolona como inhibidores de la sintasa de aldosterona.Info
- Publication number
- MX2011012199A MX2011012199A MX2011012199A MX2011012199A MX2011012199A MX 2011012199 A MX2011012199 A MX 2011012199A MX 2011012199 A MX2011012199 A MX 2011012199A MX 2011012199 A MX2011012199 A MX 2011012199A MX 2011012199 A MX2011012199 A MX 2011012199A
- Authority
- MX
- Mexico
- Prior art keywords
- symthase
- aldosterone
- inhibitors
- benzoxazolone derivatives
- benzoxazolone
- Prior art date
Links
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical class C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 title 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 title 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 title 1
- 229960002478 aldosterone Drugs 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17868009P | 2009-05-15 | 2009-05-15 | |
| US32722110P | 2010-04-23 | 2010-04-23 | |
| PCT/EP2010/056529 WO2010130773A2 (en) | 2009-05-15 | 2010-05-12 | Benzoxazolone derivatives as aldosterone symthase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011012199A true MX2011012199A (es) | 2011-12-08 |
Family
ID=42938295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011012199A MX2011012199A (es) | 2009-05-15 | 2010-05-12 | Derivados de benzoxazolona como inhibidores de la sintasa de aldosterona. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8455522B2 (OSRAM) |
| EP (1) | EP2430018B1 (OSRAM) |
| JP (1) | JP5654572B2 (OSRAM) |
| KR (1) | KR20120036850A (OSRAM) |
| CN (1) | CN102459247B (OSRAM) |
| AU (1) | AU2010247391A1 (OSRAM) |
| BR (1) | BRPI1012852A2 (OSRAM) |
| CA (1) | CA2761853A1 (OSRAM) |
| EA (1) | EA201101621A1 (OSRAM) |
| ES (1) | ES2430088T3 (OSRAM) |
| MX (1) | MX2011012199A (OSRAM) |
| WO (1) | WO2010130773A2 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120036850A (ko) | 2009-05-15 | 2012-04-18 | 노파르티스 아게 | 알도스테론 신타제 억제제로서의 벤족사졸론 유도체 |
| EA201101619A1 (ru) | 2009-05-15 | 2012-05-30 | Новартис Аг | Производные 5-пиридин-3-ил-1,3-дигидроиндол-2-она и их применение в качестве модуляторов альдостеронсинтазы и/или cyp11b1 |
| MX2011012198A (es) | 2009-05-15 | 2011-12-08 | Novartis Ag | Aril-piridinas como inhibidoras de sintasa de aldosterona. |
| US8519134B2 (en) | 2009-11-17 | 2013-08-27 | Novartis Ag | Aryl-pyridine derivatives as aldosterone synthase inhibitors |
| CA2846785C (en) | 2011-09-15 | 2020-09-22 | F. Hoffmann-La Roche Ag | New dihydroquinoline-2-one derivatives |
| SG11201809173TA (en) | 2016-04-20 | 2018-11-29 | Bristol Myers Squibb Co | Substituted bicyclic heterocyclic compounds |
| WO2018093569A1 (en) | 2016-11-03 | 2018-05-24 | Bristol-Myers Squibb Company | Substituted bicycle heterocyclic derivatives useful as romk channel inhibitors |
| AU2018230521B2 (en) | 2017-03-10 | 2022-02-03 | Embera Neurotherapeutics, Inc. | Pharmaceutical compositions and uses thereof |
| US10501449B2 (en) | 2017-06-01 | 2019-12-10 | Bristol-Myers Squibb Company | Substituted nitrogen containing compounds |
| CN112599420B (zh) * | 2020-12-28 | 2022-08-26 | 绵阳惠科光电科技有限公司 | 一种铟镓锌氧基多层结构薄膜晶体管的制备方法 |
| CN121194968A (zh) * | 2023-05-12 | 2025-12-23 | 江苏德源药业股份有限公司 | 含氮杂环类化合物及其应用 |
| WO2025024488A2 (en) * | 2023-07-27 | 2025-01-30 | Mineralys Therapeutics, Inc. | Methods of treating hypertension with a combination of lorundrostat and two or more anti-hypertensive medications |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2951135A1 (de) | 1979-12-19 | 1981-06-25 | Hoechst Ag, 6230 Frankfurt | Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
| DE3347565A1 (de) | 1983-12-30 | 1985-07-11 | Thomae Gmbh Dr K | Neue phenylessigsaeurederivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| JPS61191681A (ja) * | 1985-02-21 | 1986-08-26 | Fujisawa Pharmaceut Co Ltd | ４−イミダゾリン−２−オン誘導体 |
| US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
| US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
| CN1029479C (zh) * | 1989-11-08 | 1995-08-09 | 山之内制药株式会社 | 新型苯并噁嗪衍生物的制备方法 |
| CA2073856C (en) | 1990-01-24 | 2002-12-03 | Douglas I. Buckley | Glp-1 analogs useful for diabetes treatment |
| AU654331B2 (en) | 1991-03-30 | 1994-11-03 | Kissei Pharmaceutical Co. Ltd. | Succinic acid compounds |
| RU2086544C1 (ru) | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина |
| AU660930B2 (en) | 1991-06-21 | 1995-07-13 | Novo Nordisk A/S | (S)(+)-2-ethoxy-4-(N-(1-(2-piperidinophenyl)-3-methyl-1- butyl)aminocarbonylmethyl)benzoic acid |
| EP0618803A4 (en) | 1991-12-19 | 1995-03-22 | Southwest Found Biomed Res | POLYPEPTIDE INHIBITING PROTEIN TRANSFER TO CHOLESTERYL ESTERS, ANTIBODIES AGAINST SYNTHETIC POLYPEPTIDE AND ANTI-ATHEROSCLEROSIS PROPHYLACTIC AND THERAPEUTIC TREATMENTS. |
| US5508272A (en) | 1993-06-15 | 1996-04-16 | Bristol-Myers Squibb Company | Compounds containing a fused bicycle ring and processes therefor |
| IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
| US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
| US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
| TW313568B (OSRAM) | 1994-12-20 | 1997-08-21 | Hoffmann La Roche | |
| DE122010000020I1 (de) | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
| CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| ATE425142T1 (de) | 1999-04-23 | 2009-03-15 | Vertex Pharma | Inhibitoren von c-jun n-terminal kinasen (jnk) |
| US6677341B2 (en) | 1999-09-23 | 2004-01-13 | Pharmacia Corporation | (R)-Chiral halogenated substituted heteroaryl benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| WO2003086467A1 (en) | 2002-04-08 | 2003-10-23 | Smithkline Beecham Corporation | Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor |
| US9259390B2 (en) | 2003-08-13 | 2016-02-16 | The University Of Houston System | Parenteral and oral formulations of benzimidazoles |
| KR20060129023A (ko) * | 2004-02-23 | 2006-12-14 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 신규한 헤테로환 화합물 |
| ATE433984T1 (de) | 2004-03-26 | 2009-07-15 | Lilly Co Eli | Verbindungen und verfahren zur behandlung von dyslipidämie |
| UA90269C2 (ru) | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| US7642275B2 (en) | 2004-12-16 | 2010-01-05 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| CN101166722A (zh) | 2005-04-29 | 2008-04-23 | 惠氏公司 | 制备3,3-二取代的羟吲哚和硫代羟吲哚的方法 |
| PE20070220A1 (es) | 2005-07-29 | 2007-03-19 | Wyeth Corp | Proceso para la sintesis de moduladores del receptor de progesterona |
| KR20080037070A (ko) * | 2005-08-25 | 2008-04-29 | 쉐링 코포레이션 | 알파２ｃ 아드레날린성 수용체 효능제 |
| JP2010513482A (ja) * | 2006-12-18 | 2010-04-30 | ノバルティス アーゲー | アルドステロンシンターゼ阻害剤としてのイミダゾール類 |
| CA2695989A1 (en) | 2007-08-10 | 2009-02-19 | Glaxosmithkline Llc | Certain nitrogen containing bicyclic chemical entities for treating viral infections |
| DE102008022221A1 (de) | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
| AR072297A1 (es) | 2008-06-27 | 2010-08-18 | Novartis Ag | Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona. |
| MX2011012198A (es) | 2009-05-15 | 2011-12-08 | Novartis Ag | Aril-piridinas como inhibidoras de sintasa de aldosterona. |
| EA201101619A1 (ru) | 2009-05-15 | 2012-05-30 | Новартис Аг | Производные 5-пиридин-3-ил-1,3-дигидроиндол-2-она и их применение в качестве модуляторов альдостеронсинтазы и/или cyp11b1 |
| KR20120036850A (ko) | 2009-05-15 | 2012-04-18 | 노파르티스 아게 | 알도스테론 신타제 억제제로서의 벤족사졸론 유도체 |
-
2010
- 2010-05-12 KR KR1020117029906A patent/KR20120036850A/ko not_active Withdrawn
- 2010-05-12 EP EP10720398.6A patent/EP2430018B1/en not_active Not-in-force
- 2010-05-12 CA CA2761853A patent/CA2761853A1/en not_active Abandoned
- 2010-05-12 WO PCT/EP2010/056529 patent/WO2010130773A2/en not_active Ceased
- 2010-05-12 AU AU2010247391A patent/AU2010247391A1/en not_active Abandoned
- 2010-05-12 EA EA201101621A patent/EA201101621A1/ru unknown
- 2010-05-12 CN CN201080031607.6A patent/CN102459247B/zh not_active Expired - Fee Related
- 2010-05-12 ES ES10720398T patent/ES2430088T3/es active Active
- 2010-05-12 BR BRPI1012852A patent/BRPI1012852A2/pt not_active IP Right Cessation
- 2010-05-12 MX MX2011012199A patent/MX2011012199A/es not_active Application Discontinuation
- 2010-05-12 JP JP2012510286A patent/JP5654572B2/ja not_active Expired - Fee Related
- 2010-05-12 US US13/319,768 patent/US8455522B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN102459247A (zh) | 2012-05-16 |
| AU2010247391A1 (en) | 2011-12-01 |
| ES2430088T3 (es) | 2013-11-18 |
| US8455522B2 (en) | 2013-06-04 |
| US20120071514A1 (en) | 2012-03-22 |
| BRPI1012852A2 (pt) | 2018-06-19 |
| JP2012526769A (ja) | 2012-11-01 |
| EA201101621A1 (ru) | 2012-05-30 |
| CN102459247B (zh) | 2014-09-17 |
| CA2761853A1 (en) | 2010-11-18 |
| WO2010130773A2 (en) | 2010-11-18 |
| WO2010130773A3 (en) | 2011-01-06 |
| EP2430018B1 (en) | 2013-07-03 |
| EP2430018A2 (en) | 2012-03-21 |
| JP5654572B2 (ja) | 2015-01-14 |
| KR20120036850A (ko) | 2012-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY184008A (en) | Aryl pyridine as aldosterone synthase inhibitors | |
| MX2011012199A (es) | Derivados de benzoxazolona como inhibidores de la sintasa de aldosterona. | |
| MY156270A (en) | Substituted aminopropionic derivatives as neprilysin inhibitors | |
| IN2012DN02465A (OSRAM) | ||
| MY196427A (en) | Piperidinyl Indole Derivatives And Their Use As Complement Factor B Inhibitors | |
| MX2011012627A (es) | Derivados aminobutiricos sustituidos como inhibidores de nepralisina. | |
| IN2015DN00185A (OSRAM) | ||
| TN2014000030A1 (en) | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators | |
| MX2016000675A (es) | Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos. | |
| MX2013005533A (es) | Derivados de acido amino-bisfenil-pentanoico sustituidos como inhibidores de nep. | |
| TN2013000413A1 (en) | Glycoside derivatives and their uses for the treatment of diabetes | |
| PH12014502462A1 (en) | Complement pathway modulators and uses thereof | |
| PH12015501752A1 (en) | Substituted bisphenyl butanoic phosphonic acid derivatives as nep inhibitors | |
| MX2013011926A (es) | Derivados de glicosido y usos de los mismos. | |
| TN2014000060A1 (en) | Benzothiazolone compound | |
| TN2011000294A1 (en) | Arylcyclopropylacetamide derivatives useful as glucokinase activators | |
| TN2012000617A1 (en) | 2,3,5-trisubstituted thiophene compounds and uses thereof | |
| TN2011000573A1 (en) | Aryl pyridine as aldosterone synthase inhibitors | |
| UA106233C2 (ru) | Замещенные производные аминопропионовой кислоты как ингибиторы неприлизина | |
| PH12013500155A1 (en) | 2,3,5-trisubstituted thiophene compounds and uses thereof | |
| TN2011000593A1 (en) | Substituted aminobutyric derivatives as neprilysin inhibitors | |
| CY1115284T1 (el) | Αρυλ πυριδινη ως αναστολεας της συνθασης της αλδοστερονης |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |